Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS3 | P29474 | 1/20 | 0.40 |
| ▸ | NOS1 | P29475 | 1/20 | 0.40 |
| ▸ | NOS2 | P35228 | 1/20 | 0.40 |
| ▸ | ESR1 | P03372 | 6/20 | 0.38 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.37 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.36 |
| ▸ | DAO | P14920 | 1/20 | 0.33 |
| ▸ | HRH4 | Q9H3N8 | 4/20 | 0.33 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.33 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.33 |
| ▸ | IDO1 | P14902 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.31 |
| ▸ | SYK | P43405 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16869672 | 0.90 | HIF1A (0.37) | NOS3NOS1NOS2ESR1SORT1 | |
| SCHEMBL3518997 | 0.81 | — | — | |
| Hydrochloric Acid SCHEMBL17361360 | 0.80 | — | — | |
| SCHEMBL29057533 | 0.79 | TSHR (0.30) | TSHR | |
| SCHEMBL291612 | 0.79 | — | — | |
| SCHEMBL344424 | 0.79 | — | — | |
| Bromide SCHEMBL28380981 | 0.78 | — | — | |
| SCHEMBL26129787 | 0.78 | — | — | |
| SCHEMBL19764531 | 0.78 | HRH4 (0.36) | HRH4SMN1; SMN2 | |
| SCHEMBL27835524 | 0.78 | HIF1A (0.33) | HIF1AEPAS1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12037344-B2 | NLRP3 modulators | INNATE TUMOR IMMUNITY, INC (US) | 2024-07-16 | — | — | US | disclosed |
| US-11833210-B2 | ASH1L inhibitors and methods of treatment therewith | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2023-12-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11833210-B2 | ASH1L inhibitors and methods of treatment therewith | ASH1L, DOT1L, ASH2L | NOS3 4494/4885NOS1 4235/4885NOS2 4308/4885 |
| US-12037344-B2 | NLRP3 modulators | NLRP3, NLRP1, PYCARD | NOS3 501/4885NOS1 309/4885NOS2 407/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.